Sunday, April 03, 2011 12:38:41 PM
There's an endless supply of pills for HIV. Sorry, Feelgood. Modern medicine has defeated HIV. If you become resistant to Atripla you can take Isentress. If you become resistant to that you can try Combivir. Resistant to that? Take your pills on time, already, but try Prezista. It doesn't stop. There are easy choices for this. Talk to a HIV physician and stop Googling. Google does not replace real research unfortunately. We all know resistance occurs. But there are plenty of articles which detail that HIV patients have a normal lifespan. Guess you're not searching for those.
Accurately Measuring Recombination between Closely Related HIV-1 Genomes
http://www.ploscompbiol.org/article/info:doi%2F10.1371%2Fjournal.pcbi.1000766
This link doesn't work.
Of course all medicine have side effects. On a relative basis it will be very, very difficult to come up with an even safer version of Atripla. Gilead is hard at work on that, however. And in a few years, Atripla, Viread, Truvada, etc will all be generic and cost pennies. Certainly these drugs with over a decade of experience in millions of patients with a tremendous safety track record cannot be usurped by a preclinical 'idea'.
http://darwin.uvigo.es/download/papers/56.recModelHIV07.pdf
This paper recapitulates what everyone knows and does nothing to refute the idea that Atripla is the standard of care with a tremendous therapeutic profile.
http://www.ncbi.nlm.nih.gov/pubmed/19842973
Here is a 2-year study which shows how uncommon it is to fail HIV therapy. You really have to be irresponsible and not take your medicine. Only 4% of patients in 2 years failed. No one got AIDS in this study. Side effects are what you would normally see in any patient of 45 years. Placebo controlled studies are no longer done so telling which side affect is drug related has become impossible.
Accurately Measuring Recombination between Closely Related HIV-1 Genomes
http://www.ploscompbiol.org/article/info:doi%2F10.1371%2Fjournal.pcbi.1000766
This link doesn't work.
Of course all medicine have side effects. On a relative basis it will be very, very difficult to come up with an even safer version of Atripla. Gilead is hard at work on that, however. And in a few years, Atripla, Viread, Truvada, etc will all be generic and cost pennies. Certainly these drugs with over a decade of experience in millions of patients with a tremendous safety track record cannot be usurped by a preclinical 'idea'.
http://darwin.uvigo.es/download/papers/56.recModelHIV07.pdf
This paper recapitulates what everyone knows and does nothing to refute the idea that Atripla is the standard of care with a tremendous therapeutic profile.
http://www.ncbi.nlm.nih.gov/pubmed/19842973
Here is a 2-year study which shows how uncommon it is to fail HIV therapy. You really have to be irresponsible and not take your medicine. Only 4% of patients in 2 years failed. No one got AIDS in this study. Side effects are what you would normally see in any patient of 45 years. Placebo controlled studies are no longer done so telling which side affect is drug related has become impossible.
Recent NNVC News
- In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides • ACCESS Newswire • 05/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
